MSK Group, a leading innovator in advanced regenerative medicine and anti-aging healthcare platforms, announced that it has signed a strategic business agreement with blockchain mainnet company SymVerse Labs to establish a Real World Asset (RWA) tokenization ecosystem for K-Medical and anti-aging bio industries.

MSK Group is currently pursuing a wide range of healthcare-based future convergence businesses, including the development of advanced regenerative medicine and anti-aging medical buildings, support for licensing and R&D operations of regenerative medical institutions, and the expansion of medical tourism infrastructure. The agreement is significant in that it seeks to digitize these real-world assets (RWA) through blockchain technology, thereby promoting greater asset liquidity, a participatory ecosystem, and enhanced global investment accessibility.

SymVerse Labs is a technology company that operates its own blockchain mainnet. Leveraging its Web3 infrastructure, the company provides decentralized wallet services, smart contract-based asset management, RWA issuance and verification, as well as tailored enterprise solutions, DApp development, and consulting services.

Through this partnership, SymVerse Labs will provide the core technology to transform the real-world value of medical facilities, real estate, and regenerative medicine-related business assets into on-chain assets, enabling transparent transactions and revenue distribution among participants within a blockchain-based ecosystem.

Based on the RWA ecosystem built through their collaboration, the two companies plan to sequentially introduce structures that allow global investors to access medical industry real-world assets safely and transparently, Web3-based distribution of medical tourism revenues and assets, and on-chain participatory healthcare services for token holders.

Cho Min-soo, CEO of MSK Group, stated:
“Blockchain technology goes beyond mere adoption; it is a key tool for innovatively enhancing the trustworthiness and liquidity of medical assets. Through our partnership with SymVerse Labs, we aim to present a new business paradigm by expanding global-level medical tourism and healthcare industry models into RWAs.”

https://edu.donga.com/news/articleView.html?idxno=94417

press

press